Novartis Breaks Ground On New Production Facility In Singapore

08-Mar-2005

Novartis announced the groundbreaking for its new pharmaceutical production center located at the Tuas Biomedical Park in Singapore, a state-of-the art facility that will support long-term growth in the Asian market.

Novartis is investing approximately USD 180 million to construct the plant. When fully operational, the plant and distribution center are expected to employ more than 150 people and focus on bulk production of new and existing Novartis pharmaceutical products.

The state-of-the-art manufacturing facility is designed with LEAN manufacturing practices and systems. LEAN manufacturing is a method used to achieve reduction in overall production cycle times to speed product to market while ensuring good manufacturing practices (GMP) from raw material to finished product. The facility will employ the finest technology and engineering capabilities with the overall aim of creating a manufacturing center of excellence in Singapore.

The Novartis Pharma manufacturing facility is designed to produce a targeted capacity of 3.5 billion units annually. Annual capacity is expected to increase overtime based on product demand.

Other news from the department manufacturing

Most read news

More news from our other portals

Recognise, understand, heal: The World of Diagnostics